Purpose-Clinical testing for germline variation in multiple cancer susceptibility genes is available using massively parallel sequencing. Limited information is available for pre-test genetic counseling regarding the spectrum of mutations and variants of uncertain significance (VUSs) in defined patient populations.
INTRODUCTION
Mutations in the breast and ovarian cancer susceptibility genes, BRCA1 and BRCA2, are found in 10-20% of women with early-onset breast cancer (defined as breast cancer diagnosed under age 40) 1 . In comparison to women with postmenopausal breast cancer, women with early-onset breast cancer have a worse prognosis with increased recurrence rates, rates of distant metastases, and higher overall mortality 1 . As BRCA1/2 genetic testing is recommended for all women diagnosed with breast cancer under 40 2 , further expansion of genetic testing to other moderate and high penetrance genes is commonly considered for this group. Further, it has the potential to identify women who may benefit from targeted breast cancer screening and prevention strategies aimed at decreasing morbidity and mortality, as has been demonstrated for BRCA1/2 mutation carriers 3 .
Beyond BRCA1/2, rare highly penetrant mutations in the genes CDH1, PTEN, STK11, and TP53 lead to cancer susceptibility syndromes 4 , for which the National Cancer Care Network (NCCN) provides guidelines for genetic testing and clinical management 2 . In addition to these high risk genes, breast cancer susceptibility is associated with rare moderate penetrance mutations in an increasing number of genes, such as ATM, CHEK2, and PALB2, which confer an approximately two to five fold increased risk of breast cancer 4 . Guidelines do not delineate patient populations for whom testing for mutations in moderate risk genes is expected to be beneficial, nor how the information of this testing should be applied in clinical management of cancer risk.
Despite these limitations, clinical testing based on massively parallel sequencing (MPS) is now commercially available for many known or proposed cancer susceptibility genes 5 , 6 .
Rather than focusing on sequential testing of individual, well-studied genes due to defined clinical characteristics of the patient's personal and family histories, these tests concurrently screen a large number of genes. A lack of data about the cancer risk and penetrance in women carrying these mutations has made the translation of potential life-saving strategies used in BRCA1/2 carriers to these women problematic 7 , 8 . Whereas frequencies of BRCA1/2 mutations are well studied, data is needed on the spectrum of variants in the other cancer susceptibility genes in defined patient populations. We report, herein, data on the frequency and type of variants in a panel of cancer susceptibility genes in BRCA1/2 negative women with early-onset breast cancer.
MATERIALS AND METHODS

Patient ascertainment
The study population was ascertained from academic and community hospital sites within the Penn Cancer Network and The Karmanos Cancer Institute at Wayne State University 9 .
The majority of the patient population (253 patients, 91%) was ascertained via the Penn Cancer Network sixteen patients (6%) were from the Karmanos Cancer Institute at Wayne State University, and ascertainment data was not available for nine patients (3%). Acquisition of the patient samples was approved by the Institutional Review Boards of the corresponding institutions, and informed consent was obtained from each participant for use of their samples in genetic studies. Eligibility criteria for the study were: 1) diagnosis of breast cancer under age 40; 2) negative BRCA1/2 sequencing in a CLIA-approved laboratory; and 3) negative personal or family history of ovarian cancer. Analysis for BRCA1/2 large genomic rearrangements was not required, although negative clinical testing was available for 28% of patients.
DNA library preparation and sequencing
For each patient, one microgram of constitutional DNA was blunt ended and ligated with adaptors-embedded indexes. DNA quality, fragment size and concentration were measured with an Agilent 2100 Bioanalyzer. DNA libraries of sufficient quality were pooled precapture to 24-plex and hybridized to a custom designed Agilent SureSelect target library covering all coding exons and the flanking 10 base pairs of 22 genes. The genes included 20 study genes plus BRCA1 and BRCA2 and were: 1) high penetrance breast cancer susceptibility genes (CDH1, PTEN, STK11, TP53); 2) genes known to cause other cancer susceptibility (CDKN2A, MLH1, MSH2, MSH6, PMS2); 3) genes known or postulated to be moderate penetrance cancer susceptibility genes (ATM, BARD1, BRIP1, CHEK2, FAM175A,MRE11A, NBN, RAD50, PALB2, RAD51C); and 4) MUTYH, which leads to autosomal recessive polyposis.
Massively parallel sequencing data analysis
Raw sequencing data were aligned to the hg19 assembly of the human genome using Burrows-Wheeler Aligner (BWA) for short-read alignment (http://sourceforge.net/projects/ bio-bwa/files/) 10 . BAM files were processed with Genome Analysis Toolkit (GATK) for detection of single nucleotide variants (SNVs) and insertion/deletion variants (indels) (http:// www.broadinstitute.org/gatk/download) 10 , 11 and annotated with ANNOVAR (http:// www.openbioinformatics.org/annovar/annovar_download.html) 10 . Data was additionally analyzed using Pindel to improve sensitivity for medium sized indels (http:// gmt.genome.wustl.edu/pindel/0.2.4/install.html) 10 and xhmm for large genomic rearrangements (https://atgu.mgh.harvard.edu/xhmm/download.shtml) 12 . Quality control measures were calculated using Picard Tools (http://sourceforge.net/projects/picard/files/). Samples were sequenced to a mean coverage of 224×. Three samples were removed from the analysis for having >10% of targets with 0% coverage or <50% of targets with >10× coverage.
To identify all single nucleotide variants, small and medium sized insertion/deletions (indels) and large genomic rearrangements, variants were filtered to remove synonymous missense variants and intronic variants. 10 .
Variant classification
In order to classify variants into a five-tiered system, a pipeline was developed which integrated posterior probability of pathogenicity data (when available), publically available database calls, protein position of the variant in a functional domain, in silico analysis 10 
Validation of pipeline
In order to determine the efficiency and accuracy of our sequencing platform and bioinformatics and variant classification pipeline, we analyzed samples with variants identified by clinical sequencing in BRCA1, BRCA2, MSH2, or PALB2; these included two nonsense mutations, four indels, two large genomic rearrangements, and 34 single nucleotide variants. 100% of the 42 known variants were identified and correctly classified. For each identified deleterious and likely deleterious variant in a study sample, a separate stock aliquot of the patient's DNA sample from the aliquot used for MPS was used for Sanger sequencing of the genomic region containing the variant. Primers were developed using NCBI Primer Design software and PCR products were generated with Platinum Taq polymerase.
Statistical analysis of clinicopathogical variables
Statistical comparisons were made regarding the frequency of patients with certain clinical or pathological features within groups of patients as determined by variant status using a two-tailed Fisher's exact test. Statistical comparisons of age, Penn II scores, and BOADICEA scores between groups of patients depending on variant status was performed using a two-tailed, type 2, Student's t-test. Comparisons were run for deleterious/likely deleterious variant positive versus deleterious/likely deleterious variant negative (including the VUS positive patients in the latter group) and deleterious/likely deleterious variant positive versus deleterious/likely deleterious variant and VUS negative (excluding the VUS positive patients from both groups).
RESULTS
Characteristics of the early-onset breast cancer study population studied are shown in Table  1 . Of the 278 patients, 169 (61%) had at least one variant found at <0.1% allele frequency in control public databases. After variant classification, 86 patients (31%) were found to have at least one deleterious variant, likely deleterious variant, or VUS ( Figure 1 ). Thirty-one patients (11%) overall were identified to carry a total of 34 deleterious or likely deleterious variants, 53 patients (19%) had 57 VUSs (including 49 with a VUS only), and six patients (2.2%) were heterozygous for MUTYH variants.
Seven patients were identified to have deleterious or likely deleterious variants in a high penetrance cancer susceptibility gene ( Figure 1 , Table 2 ). Two patients were found to carry a known pathogenic TP53 mutation (Figure 2a, b) . Two patients, including one African American, were found to carry likely deleterious variants in TP53. One patient was identified to have a large genomic rearrangement deleting exon 5 of MSH2 leading to an inframe deletion of 65 amino acids of the DNA interacting domain of MSH2. A patient with a history of both early-onset breast cancer and sarcoma was found to carry a known pathogenic missense mutation in CDKN2A. Finally, one patient, with a personal history of early onset colon cancer and two primary breast cancers, was found to be a compound heterozygote for a known pathogenic mutation and a likely deleterious variant in MUTYH.
Twenty-four patients were found to have deleterious or likely deleterious variants in genes in which mutations have been associated with a moderate risk of breast cancer. The majority of deleterious or likely deleterious variants in moderate penetrance genes were found in ATM and CHEK2 ( Figure 1 , Table 2 ). Single deleterious or likely deleterious variants were found in ATM in seven patients and in CHEK2 in nine patients. One patient was found to carry deleterious variants in both ATM and CHEK2; of note both variants also were found in her brother with early onset prostate cancer (Figure 2c ). In addition, one patient was found to carry two likely deleterious variants in trans in CHEK2. The remaining six patients had deleterious variants in MRE11A (2), BARD1 (1), BRIP1 (1), NBN (1), and RAD50 (1).
Twenty-seven patients carried a VUS in a high penetrance cancer susceptibility gene, and three of those patients also had a deleterious or likely deleterious variant. Nine patients were found to have a single VUS in BRCA1 or BRCA2, three patients in TP53 and 12 patients in MLH1, MSH2, MSH6, or PMS2; no VUSs were found in CDH1, CDKN2A, STK11 or PTEN. Three additional patients each carried two VUSs in a high penetrance cancer susceptibility gene. Twenty-six patients were found to have VUSs in moderate penetrance cancer susceptibility genes, ATM, BRIP1, CHEK2, FAM175A, MRE11A, NBN, PALB2, RAD50, and RAD51C; no VUSs were found in BARD1. Finally, six patients carried a single deleterious variant or VUS in MUTYH (Figure 1 ). Three patients were heterozygous for the same known pathogenic MUTYH mutation and three were heterozygous for VUSs in MUTYH.
The proportion of patients identified to have a clinically reportable variant varied by race, such that 28% of self-reported white patients were found to have at least one reportable variant versus 37% of non-white patients (Figure 1, p=NS) . The proportion of patients with a deleterious or likely deleterious variant did not vary significantly between white and nonwhite patients (13% versus 6%, p=NS). The proportion of non-white patients found to carry a VUS was statistically significantly higher than the proportion of white patients, 31% versus 15% (p=0.01). Of the 66 African Americans, 7.5% carried a deleterious or likely deleterious variant, which was not statistically significantly different than the proportion of white patients. Of the 27 Ashkenazi Jewish individuals, 22% were found to have a deleterious or likely deleterious variant, compared with 10% of the 234 non-Ashkenazi Jewish individuals (p=NS).
In comparison to deleterious or likely deleterious variant negative patients, there was a statistically significant increase in the rate of second primary malignancies (excluding nonmelanoma skin cancers, Multiplex panel MPS-based mutation detection accurately identifies patients with mutations in genes leading to inherited cancer predisposition 18 and has been used successfully to identify the spectrum of variants in single populations of patients with colon, ovarian and uterine cancers 19 -21 . Recently, studies have reported findings using multiplex panels in heterogeneous groups of BRCA1/2 negative patients, either in randomly selected 22 , 23 or consecutive 24 patients from high risk genetics clinics or in all patient samples submitted to commercial testing laboratories 23 , 25 . Excluding monoallelic MUTYH carriers as the associated cancer risks are controversial 26 , these studies of predominantly white individuals found that between 3.4-9.5% of BRCA1/2 negative patients carried deleterious or likely deleterious variants in panel genes 22 -25 . We found a deleterious or likely deleterious variant rate of 11% using a custom 22-gene panel in a well-characterized group of 278 early-onset breast cancer patients, including 66 African Americans, consistent with an increased likelihood of finding cancer susceptibility mutations in a younger, affected patient population. We found that 2.2% were heterozygous MUTYH carriers, similar to the LaDuca study rate of 1.7% 25 and the reported population carrier frequency of MUTYH mutations of 1.1% (range 0-2%) 27 .
Our variant classification algorithm found a 19% VUS rate in the early-onset breast cancer patients using a pipeline integrating multiple data sources. Kurian 23 . Given that VUSs cause confusion and anxiety for both patients and practitioners, incorporating various data sources to support calls and exploring novel variant classification methods will be increasingly necessary going forward.
In our study, we found that seven patients (2.5%) carried clinically reportable variants in TP53. Regarding the four individuals with TP53 deleterious or likely deleterious variants, two had family histories meeting Chompret criteria, one was diagnosed at age 30 with bilateral breast cancer and one had a family history of late-onset sarcoma and multiple lateonset bilateral breast cancer cases; all were ascertained prior to 2007. No mutations were found in the genes associated with other well characterized cancer susceptibility syndromes, PTEN, STK11, and CDH1. Many of the patients in this study population were reviewed in a genetics conference at a tertiary care institution where there is high index of awareness for these phenotypes, and patients with known mutations in these genes were excluded from the present study. Their mutation rates may differ in unselected populations.
With regard to other high risk cancer susceptibility genes, one patient with a family history of melanoma was found to have a mutation in CDKN2A; excess breast cancer has been described in families with CDKN2A mutations 28 . One patient was found to have a likely deleterious variant in MSH2 and one patient was a compound heterozygote for a MUTYH pathogenic mutation and a likely deleterious variant; the breast cancer risks associated with mutations in MUTYH and the mismatch repair genes such as MSH2 is controversial 29 , 30 . It is possible that these mutations did not contribute to the development of breast cancer in these individuals. Further study of the breast cancer risks associated with these gene mutations is needed. These data highlight the importance of determining the clinical management of individuals identified to have mutations by multiplex panel testing in genes not classically associated with the patient's phenotype or pedigree.
Regarding moderate risk breast cancer susceptibility genes, we found ATM mutations in 2.9% (n=8), CHEK2 founder mutations (1100delC, I157T and c.444+1G>A) in 2.5% (n=7), and other CHEK2 mutations in 1.4% (n=4) of patients. In addition, we found two patients with MRE11A mutations and single patients with mutations in BARD1, BRIP1, NBN, and RAD50, respectively. Interestingly, we did not identify any patients with PALB2 or RAD51C mutations. It is possible that the ethnic diversity of our population (28% nonwhite) is responsible for the variability in mutation frequency between ours and other studies 31 -35 . Our study demonstrates that mutations in individual moderate penetrance genes outside of ATM and CHEK2 are likely very infrequent in patients with early-onset breast
cancer.
There are a number of important limitations to our study. Our study design excluded individuals with a personal or family history of ovarian cancer and it is possible that such early-onset breast cancer patients will have a different spectrum of mutations. Our study also did not include genes recently proposed to contribute to breast cancer susceptibility such as BLM 36 , FANCC 36 , and XRCC2 37 or ovarian cancer susceptibility such as RAD51D 38 , and mutations in these genes could be present in our study population. Massively parallel sequencing approaches have limitations in the identification of large genomic rearrangements and therefore these types of variants could still be present in our patient population. Finally, as the majority of patients in the study had a family history of breast cancer and were ascertained through two health systems and affiliated hospitals, our findings may not be generalizable to patients with early-onset breast cancer ascertained through population based studies.
Overall, our results suggest that at least 11% of BRCA1/2 negative patients with early-onset breast cancer may have a causative mutation in high or moderate penetrance genes found on multiplex panel testing. A higher incidence of other malignancies may occur in early-onset breast cancer patients with these mutations, and further study of these risks in larger populations could allow for more rational decision making regarding cancer screening and medical and/or surgical preventive treatments for these patients 3 , for example prophylactic contralateral mastectomy at the time of a breast cancer diagnosis. In addition, it is now understood that the tumors in BRCA1/2 carriers show increased sensitivity to PARP inhibitors and platinum agents due to synthetic lethality 39 . Given that many of the other cancer susceptibility genes studied here also play a role in double stranded DNA repair, it is possible that tumors of carriers of some of these other gene mutations may also show increased sensitivity to these agents 40 .
Although our sample size was too limited to define the breast and non-breast cancer risks for family members of individuals with mutations in moderate penetrance genes, the Penn II and BOADICEA model prior probability scores were statistically significantly higher in deleterious or likely deleterious variant positive patients and this may reflect the stronger family histories of breast and/or other cancers in patients with deleterious mutations. Additional studies are needed to determine if true negative family members of those with mutations in the genes studied here can be counseled that they are at population risk for breast and other gene specific cancers, as is the case for BRCA1/2 3 .
Our results highlight the critical need for large consortia to delineate the expected mutation rates, penetrance, and associated cancer risks for moderate risk genes found on cancer susceptibility genetic testing panels in well-defined clinical populations, keeping in mind the relatively lower penetrance of some of these mutations and the possibility for segregation of multiple risk alleles. In addition, consortia will be needed to pool data to study and develop clinical recommendations for patients carrying these mutations and their family members.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. Germline DNA from 278 BRCA1/2 negative patients with early onset breast cancer (earlyonset breast cancer) was isolated and subjected to massively parallel sequencing using a custom capture for the indicated genes in Bin A and Bin B. Sequencing data was analyzed with a custom bioinformatics pipeline and deleterious variants were called into classes (D = Deleterious, LD = Likely Deleterious, VUS = Variant of Uncertain Significance, LB = Likely Benign, and B = Benign). Inset: Proportion of patients self-reported as "White" or "Non-white" with deleterious or likely deleterious variants, VUSs only, or no reportable deleterious or likely deleterious variants or VUSs. The MUTYH heterozygous carriers included three patients heterozygous for a deleterious variant and three patients heterozygous for a VUS. Table 1 Clinical and pathological characteristics of patients 
